New cocktail aims to tame tough breast cancer
NCT ID NCT06027268
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tests a four-drug combination (trilaciclib, pembrolizumab, gemcitabine, and carboplatin) in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The goal is to see how well the treatment shrinks tumors and how safe it is. About 36 adults with this aggressive cancer type will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.